It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The expression and biological function of junctional adhesion molecule-like protein (JAML) in colorectal cancer (CRC) remain unclear. Paraffin tissue samples from 50 cases of CRC were collected to determine the expression of JAML. JAML was overexpressed or knock-down in CRC cells to evaluated the proliferation, migration and invasion in vitro and in vivo. Western-blot and others were applied to explore the mechanisms. The study showed that JAML was highly expressed within cancer tissues in 50% (25/50) of patients with CRC, and was correlated with higher TNM stage (p < 0.05). Patients of JAML-high group had poorer overall survival compared to JAML-low group (p = 0.0362, HR = 0.4295, 95% CI of 0.1908–0.9667). The tumour infiltrating lymphocytes (TILs) was lower in the JAML-high group than in the JAML-low group (p < 0.05). Overexpression of JAML promoted the proliferation, migration, and invasion of CRC by activating the PI3K-AKT-mTOR signalling pathway both in vitro and in vivo. TILs were reduced in JAML-high tumour tissues by decreasing chemokines such as CCL20 and CXCL9/10/11. Our study identified JAML, a potentially ideal target that is specifically highly expressed in CRC tissues, which promoted tumour proliferation, impaired T-lymphocytes infiltration, provided a promising therapeutic strategy for patients with CRC.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Central Hospital Affiliated to Shandong First Medical University, Department of Oncology, Jinan, People’s Republic of China (GRID:grid.410587.f); Shandong University, Department of Oncology, Jinan Central Hospital, Jinan, People’s Republic of China (GRID:grid.27255.37) (ISNI:0000 0004 1761 1174); Central Hospital Affiliated to Shandong First Medical University, Research Center of Translational Medicine, Laboratory Animal Center, Jinan, People’s Republic of China (GRID:grid.410587.f)
2 Central Hospital Affiliated to Shandong First Medical University, Department of Oncology, Jinan, People’s Republic of China (GRID:grid.410587.f); Shandong First Medical University, Department of Clinical Medicine, Jinan, People’s Republic of China (GRID:grid.410587.f)
3 Central Hospital Affiliated to Shandong First Medical University, Department of Oncology, Jinan, People’s Republic of China (GRID:grid.410587.f); Central Hospital Affiliated to Shandong First Medical University, Research Center of Translational Medicine, Laboratory Animal Center, Jinan, People’s Republic of China (GRID:grid.410587.f)
4 Central Hospital Affiliated to Shandong First Medical University, Department of Oncology, Jinan, People’s Republic of China (GRID:grid.410587.f)
5 Shandong University, Department of Oncology, Jinan Central Hospital, Jinan, People’s Republic of China (GRID:grid.27255.37) (ISNI:0000 0004 1761 1174); Central Hospital Affiliated to Shandong First Medical University, Research Center of Translational Medicine, Laboratory Animal Center, Jinan, People’s Republic of China (GRID:grid.410587.f)
6 Central Hospital Affiliated to Shandong First Medical University, Department of Pathology, Jinan, People’s Republic of China (GRID:grid.410587.f)
7 Central Hospital Affiliated to Shandong First Medical University, Research Center of Translational Medicine, Jinan, People’s Republic of China (GRID:grid.410587.f)
8 Qilu Hospital of Shandong University, National Key Laboratory for Innovation and Transformation of Luobing Theory, The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Department of Cardiology, Jinan, People’s Republic of China (GRID:grid.452402.5) (ISNI:0000 0004 1808 3430)
9 Central Hospital Affiliated to Shandong First Medical University, Department of Oncology, Jinan, People’s Republic of China (GRID:grid.410587.f); Shandong University, Department of Oncology, Jinan Central Hospital, Jinan, People’s Republic of China (GRID:grid.27255.37) (ISNI:0000 0004 1761 1174)